Cupric Nitrate,Basic

We are Cupric Nitrate,Basic CAS:12158-75-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product name: 
Cupric Nitrate,Basic

 

CAS No.: 12158-75-7

Molecular Formula: 

Cu(NO3)2·3Cu(OH)2

Molecular Weight: 480.22
 

Characters: Light blue powder, insoluble in water and alcohols, soluble in diluted acid and ammonia water.
 

Specifications:

Cupric Nitrate,Basic Special-purpose grade Technical grade
Item Spec. Spec.
Assay(as Cu) % 52.5-53.6 52.5-53.6
Nitrates(NO3) % 25.3-26.3 25.3-26.3
Na% ≤0.5 ≤0.5
Water insoluble% ≤0.3 ≤0.3
pH-value(100g/L) 5.5-7.5 5.5-7.5
Granularity(UM) D50≤1.5

Product Usage: It is used for new-generation auto airbag.

Packaging: In 25Kg/woven bag lined with double-layer plastic bag, closed tightly.

Storage Precautions: The toxic chemicals. Avoid inhalation of the product using the dust, avoid contact with eyes and skin. Should be sealed in dry place.

Cupric Nitrate,Basic


Related News: High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.(3-chlorophenyl)-(3,4-dimethoxyphenyl)methanone CAS:116412-84-1 High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.2-Methoxy-4-methylpyridine High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.2,3-dimethylbenzoic acid CAS:603-79-2 High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.

Related Products
Product Name
ethyl 2-(4-hydroxyphenyl)-4-methyl thiazole-5-carboxylate View Details
2-Bromo-5-fluorobenzyl bromide View Details
Optical Brightening Agent CBS-CL View Details
N,N’-Bis-boc-1-guanylpyrazole manufacturer methanethiol manufacturer L-Histidine Monohydrochloride Monohydrate manufacturer 2-Bromo-3-Fluoro-6-Picoline manufacturer Methyl 2-aminothiazole-5-carboxylate manufacturer